Important Notice: Euthyrox^® U.S. Discontinuation

Following Provell Pharmaceuticals' discontinuation of commercialization regarding Euthyrox^® earlier in 2025, EMD Serono has made the difficult decision not to continue commercialization of Euthyrox^® (Levothyroxine tablet) in the United States. This decision was not based on any safety, quality, or efficacy concerns with the medication. This decision was based on business considerations following the disruption to our distribution partnership.

Current Supply Status: Please note that the New Drug Application for Euthyrox^® was withdrawn in November 2025 and it will become increasingly difficult to access remaining stock available in the US with expiration date of September 2026.

What You Should Do: We encourage patients to contact your healthcare provider promptly to discuss alternative levothyroxine medications. The FDA has approved several therapeutically alternative options that work the same way as Euthyrox^®. Your healthcare provider can help you find the best alternative for your specific needs.

Important Reassurance: This discontinuation does not mean there's anything wrong with Euthyrox^®. The medication itself, and its quality, safety, and effectiveness remain unchanged. Multiple effective alternatives are available to ensure continuity of your thyroid treatment. We strongly recommend working with your healthcare provider on transition planning.

If you have questions, please contact our Medical Information team:

Phone: 1-888-275-7376 (Mon-Fri, 8:00 AM 5:30 PM ET)

Email: emediusa@emdserono.com

A Personal Note from Our Team:

We understand that this discontinuation affects real people who depend on Euthyrox^® for their daily health and well-being. While we cannot change our business decision, we are genuinely committed to supporting you through this transition. You are not alone in this process, and effective alternatives are available. We recommend working with your healthcare provider on transition planning.